There is no single kisspeptin dose that human research establishes for routine care. Published studies used kisspeptin-10 or kisspeptin-54, given as a bolus (one dose at once) or an infusion (a dose delivered gradually), through a vein or under the skin. Those choices changed the hormone response. They do not convert into one dependable syringe amount for home use.
Kisspeptin is a peptide, a short chain of amino acids that acts as a signal. It prompts release of gonadotropin-releasing hormone (GnRH), the brain's message to the pituitary, a hormone-control gland below the brain. The pituitary then releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH), two hormones involved in reproduction. Our guide to what kisspeptin does explains that pathway; here, the question is what the dose numbers really mean.
Why there is no standard kisspeptin dose
A useful dose cannot be separated from the peptide form. Kisspeptin-10 is the active ten-amino-acid tail. Kisspeptin-54 is the longer naturally circulating form. They reach the same receptor, a docking point on a cell, but they do not remain in the blood for the same length of time.
Route matters too. An intravenous (IV) dose goes directly into a vein. A subcutaneous dose goes into the tissue under the skin. An hours-long pump infusion is a different exposure from one injection, even when both are described with similar-looking numbers.
The goal and the person matter just as much. Small studies enrolled healthy men, healthy women at different points in the menstrual cycle, women whose periods had stopped because brain hormone signaling was suppressed, and patients in closely monitored fertility treatment. A number from one group does not become a standard for another.
Kisspeptin doses used in human studies
These figures describe experiments, not a menu. KP-10 and KP-54 are study shorthand for kisspeptin-10 and kisspeptin-54. A microgram is a measure of mass. A nanomole and a picomole measure numbers of molecules; a picomole is one-thousandth of a nanomole. When a unit is written per kilogram, the study scaled it to body weight; that still does not reveal the concentration or syringe units of a prescription.
| Study | Form and participants | Dose and route used | What researchers measured |
|---|---|---|---|
| George et al., 2011 | KP-10; small groups of healthy men | IV boluses of 0.01–3 micrograms/kg; IV infusions of 1.5 or 4 micrograms/kg/hour for up to 22.5 hours | LH response, LH pulses, and testosterone |
| Jayasena et al., 2011 | KP-10; healthy men and women | IV boluses of 0.3–10 nmol/kg; women also received under-skin boluses of 2–32 nmol/kg and IV infusions | Hormone response by sex and menstrual-cycle phase |
| Dhillo et al., 2005 | KP-54; six healthy men | IV infusion of 4 pmol/kg/minute for 90 minutes | LH, FSH, testosterone, and time in the blood |
| Dhillo et al., 2007 | KP-54; healthy women | One under-skin dose from 0.2–6.4 nmol/kg | LH response across menstrual-cycle phases |
| Jayasena et al., 2009 | KP-54; women whose periods had stopped because brain hormone signaling was suppressed | 6.4 nmol/kg under the skin twice daily for two weeks | Initial hormone response and its decline with repetition |
| Jayasena et al., 2014 | KP-54; 53 women in in vitro fertilization (IVF) care | One under-skin dose of 1.6, 3.2, 6.4, or 12.8 nmol/kg | Egg maturation in a monitored IVF cycle |
For a closer look at the shorter fragment, the kisspeptin-10 guide walks through its small dose-response studies without turning them into a home protocol.
A PT-141 dose is not a substitute
Kisspeptin and PT-141 can appear in the same sexual-health conversation, but their dose numbers cannot be swapped. PT-141 acts on melanocortin receptors involved in sexual response. Kisspeptin starts farther upstream in reproductive-hormone signaling. A familiar dose for one says nothing about the right amount of the other.
Fresh 2026 data makes the pattern clearer
As of September 9, 2026, the day this article was written, the newest directly relevant dose-pattern study was published August 4, 2026, in the European Journal of Endocrinology. It enrolled 15 healthy men and tested kisspeptin-10 through an under-skin infusion pump, not ordinary take-home injections (Yeung et al., 2026).
Seven men completed eight-hour infusions ranging from 1.25 to 10 nmol/kg/hour. A four-man arm used 180 nmol/hour continuously for five days; the LH response was smaller by day five. A seven-man arm used 150 nmol/hour for eight hours a day with a 16-hour break, and LH and FSH remained above the control response through day 12.
That study does not establish a routine kisspeptin dose. It shows something more useful: exposure pattern can change the response, and a pump study in healthy volunteers cannot be reduced to a single injection number.
The four-minute half-life is not a schedule
Half-life means the time it takes the body to clear half of a dose. After a monitored IV infusion, kisspeptin-10 had a measured half-life of 3.8 ± 0.3 minutes in men and 4.1 ± 0.4 minutes in women. Kisspeptin-54 lasted longer, about 27.6 minutes in the 2005 study.
The signal can outlast the peptide in the blood. In the 2011 KP-10 work, LH peaked after the peptide itself had begun disappearing, and testosterone rose later still. A short half-life therefore does not tell a patient how often an injection belongs in a prescription.
Repetition can also change the response. In the 2009 KP-54 study, twice-daily dosing initially raised LH and FSH, but the response had fallen sharply by the end of two weeks. This is called desensitization, meaning the signaling system answers less strongly after repeated exposure. More frequent exposure is not automatically a stronger plan.
What the prescription has to decide
The prescriber has to settle five connected questions: the clinical goal, whether KP-10 or another form is being considered, the route, the amount, and how the response will be followed. Hormone results, menstrual-cycle context, fertility plans, medications, and pituitary, ovarian, or testicular conditions can all change that judgment.
Kisspeptin has no FDA-approved U.S. product. An FDA briefing on kisspeptin-10 states that it is not a component of an FDA-approved drug. Kisspeptin through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A compounded medication is prepared by a licensed pharmacy for an individual prescription. A licensed provider may still prescribe it when appropriate; that decision is between you and your doctor.
At Promise, a licensed provider reviews every request and not everyone qualifies. If a prescription is written, its label—not a dose copied from an IVF paper, an infusion study, or an online forum—governs the amount, timing, and route. The kisspeptin product page is the starting point for that review.
How to read a kisspeptin number online
A dose claim is only interpretable when it names the peptide form, route, unit, population, and schedule. Leaving out any one of those details can make two very different experiments look alike. Milligrams in a vial describe total contents, not the amount intended for one use.
The plain answer remains the safest one: published numbers show how researchers asked specific questions under monitoring. They do not establish a universal kisspeptin dosage, and they do not replace the directions tied to an individual prescription. None of these study amounts transfer to the pills sold online as kisspeptin supplements, which have no human absorption data behind them.